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Abstract
Purpose: Early detection is essential for treatment plans before
onset of metastatic disease. Our purpose was to demonstrate
feasibility to detect and monitor estrogen receptor 1 (ESR1) gene
mutations at the single circulating tumor cell (CTC) level in
metastatic breast cancer (MBC).
Experimental Design: We used a CTC molecular character-
ization approach to investigate heterogeneity of 14 hotspot
mutations in ESR1 and their correlation with endocrine resis-
tance. Combining the CellSearch and DEPArray technologies
allowed recovery of 71 single CTCs and 12 WBC from 3
ER-positive MBC patients. Forty CTCs and 12 WBC were
subjected to whole genome amplification by MALBAC and
Sanger sequencing.
Results: Among 3 selected patients, 2 had an ESR1 mutation
(Y537). One showed two different ESR1 variants in a single CTC
and another showed loss of heterozygosity. All mutations were
detected in matched cell-free DNA (cfDNA). Furthermore, one
had 2 serial blood samples analyzed and showed changes in both
cfDNA and CTCs with emergence of mutations in ESR1 (Y537S
and T570I), which has not been reported previously.
Conclusions:CTCs are easily accessible biomarkers tomonitor
and better personalize management of patients with previously
demonstrated ER-MBC who are progressing on endocrine thera-
py. We showed that single CTC analysis can yield important
information on clonal heterogeneity and can be a source of
discovery of novel and potential driver mutations. Finally, we
also validate a workflow for liquid biopsy that will facilitate early
detection of ESR1 mutations, the emergence of endocrine resis-
tance and the choice of further target therapy. Clin Cancer Res; 1–8.
!2017 AACR.
Introduction
Breast cancer is the most frequent cancer and the leading cause
of cancer-related death among women. Despite advances in
prevention, diagnosis, and adjuvant treatment, about 30% of
breast cancer patients develop metastatic disease (1). Recent
advances suggest that the presence of different tumor cell clones
plays an important role inmetastatic progression and resistance to
chemotherapy (2). According to the clonal theory of tumor
evolution, cancer is an evolving process (3), and the selective
pressure exerted by multiple lines of treatment may lead to
selection of much more aggressive subclone populations or even
those with an acquired drug resistance (4).
About 75%of breast cancers express the estrogen receptor (ER);
and, acting on this signaling pathway is a key treatment strategy.
The main endocrine therapeutic approaches are: (i) selective ER
modulators (SERM); (ii) inhibitor of aromatase (AI); and (iii)
selective ER downregulators (SERD; ref. 5). However, in 20% to
25% of metastatic breast cancer (MBC) patients, endocrine ther-
apy failure has been reported after several lines of treatment, and
new targeted therapies have been approved to be combined with
hormone therapy (6–8). Several molecular mechanisms of resis-
tance may be involved, including downregulation and posttrans-
lational modification of the ER encoded by the ESR1 gene (9).
Because ESR1mutations are rare, occurring in only 1%of primary
breast cancer, their ability to confer endocrine resistance has been
speculated formany years (10). However, inmetastatic tissues the
incidence of such mutations is estimated at 20% (11). In the last
several years, 14 ESR1 point mutations have been reported,
mainly localized in the ligand-binding domain (LBD) including
3 hotspot mutations in codons 380, 537, and 538. Functional
study of these mutations showed an ER ligand-independent
activity, highlighting their role in acquired endocrine resistance
(12, 13). Therefore, genomic characterization of distant metasta-
sis may provide clinically useful information for the selection of
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specific therapeutic treatments (14, 15). Even though genetic
testing on repeated metastatic biopsies may not be representative
of the whole tumor mass and leads to an underestimation of
tumor heterogeneity (16).
Liquid biopsy using either circulating tumor cells (CTC) or cell-
free tumor DNA (ctDNA) has become one of the most sensitive
approaches tomonitor tumormolecular evolution (17, 18). CTCs
can be isolated noninvasively over time (19) and over the past
decade, the prognostic value of CTCs has been shown in meta-
static breast, colorectal, and prostate cancer (20–26). Significant
advances in cancer diagnosis and in the evaluation of disease
progression and treatment can be reached with single CTC anal-
ysis because of the improvements made in single-cell genomics
analysis (27). Currently, there are few techniques available for
single cell isolation, including micromanipulation, laser micro-
dissection, and high-throughput fluorescence-activated cell sort-
ing (FACS). These approaches have several disadvantages, includ-
ing inadequate detection sensitivity for CTC population, a
required high number of cells as a starting population and are
manual and laborious methods (28–30).
We decided to study the molecular features of CTCs in patients
with hormone-receptor–positive (HRþ)MBC receiving endocrine
therapy. We planned to validate a laboratory workflow for single
CTCdetection, isolation andmolecular analysis by combining the
sequential use of CellSearch (20–26), DEPArray systems (31, 32)
and MALBAC techniques (33). The purpose of this study was to
investigate the incidence and heterogeneity of ER expression and
to evaluate the detection of ESR1 mutations in individual CTCs.
We also planned to compare our single CTC data with matched
cfDNA.
Materials and Methods
Patients and sample collection
Thirty MBC patients were enrolled at the Department of Med-
ical Oncology, Thomas Jefferson University in Philadelphia,
between February and September 2015. Only patients with a
primary ER-positive MBC were included. Clinical parameters
included sex, age at surgery, differentiation grade, lymph node
metastasis, distant metastasis, TNM stage, and histology. Proges-
terone receptor (PR) and ER status of the primary tumor and of
available metastases were recorded. All subjects gave informed
consent, and the study was approved by the Institutional Review
Board. For each patient, 10 mL of blood was collected in two
CellSave tubes (Veridex, LLC) for enrichment, enumeration, and
molecular characterization of CTCs using the FDA-approved
CellSearch System. All samples were taken at least 5 days after
the last treatment. Matching primary tumor tissues were tested for
the presence ofmutations in ER receptor before starting hormonal
therapy.
Cell lines
Two human breast cancer cell lines (MCF-7 and FC-IBC-02)
and a prostate cancer cell line (C4-2) were used to validate whole
genome amplification experiments. MCF-7 cells weremaintained
in DMEM containing 10% (v/v) FBS, 100 units/mL penicillin and
100 mg/mL streptomycin. FC-IBC-02 primary cells were isolated
from pleural effusion of IBC patients and cultured in Ham's F12
with 10% (v/v) FBS, 5 mL insulin and 100 mg/mL of hydrocorti-
sonewith antibiotic antimicotic. TheC4-2 cell linewas cultured in
RPMI with 2.5% to 10% (v/v) FBS as previously described (34).
All cell lines were maintained in T-25 or T-75 flasks using pre-
scribed cell culture conditions [5% (v/v) CO2, 37"C].
Quality control and experimental procedure validation
Single tumor cells were obtained from MCF-7 and FC-IBC-02
cell lines through micromanipulation and from C4-2 cell line by
serial dilution. All collected cells were processed for MALBAC.
Meanwhile, 30 pg of genomic DNA carrying the V600E mutation
in the BRAF gene was used as MALBAC-positive control for all
WGA products. To validate the CellSearch ability to capture CTC,
100 C4-2 cells were spiked into a healthy donor blood sample.
Captured C4-2 cells together with WBC from the healthy donor
were loaded on the DepArray cartridge to achieve single cell
isolation and capture.
DEPArray system is a semiautomated system that allows the
isolation of rare fluorescently labeled cells. An electric field is
generated on the surface of a silicon chip directly interfaced to a
microfluidic chamber containing the cell suspension and an array
of electrodes. Each electrode can be programmed to achieve a cage
of dielectrophoresis, inside of which single CTC can be trapped
and then analyzed individually.
Individual C4-2 and WBC cells were subsequently MALBAC
amplified and screened for 7 knownmutations in the AR, CDH1,
PIK3C3, NCOR2, ERBB2, CDK4, and ETV1 genes by Sanger
sequencing. C4-2 and WBC genomic DNA from a healthy donor
also were used to confirm the 7 variants by Sanger sequencing.
Enrichment, immune labeling, and enumeration of CTCs
Standard CellSearch protocol for CTCs enrichment and enu-
meration was used according to the manufacturer's instructions.
Briefly, CTCs were enriched on the CellTracks Autoprep using
ferrofluid conjugated with EpCAM antibody. Cells were stained
with fluorescently labeled monoclonal antibody for cytokeratin
CK8-, CK18-, CK19-FITC aswell as for leukocyte common antigen
CD45-APC and nuclear-stained with DAPI. Moreover, ER expres-
sion on MCF-7 cells and CTCs was assessed by staining the cells
with a PE-conjugated anti-ER nuclear antibody.
Because the DEPArray system (Silicon Biosystem) provides the
analysis of only 66% of the loaded volume, to optimize single
CTC recovery rate, only patients exhibiting >20 CTCs (ERþ and
ER#) were processed.
Translational Relevance
Current treatment strategies, including single-agent endo-
crine agents or combinations with CDK4/6 inhibitors or
mTOR inhibitors, have increased capabilities of effective treat-
ment of patients with hormone-receptor–positive metastatic
breast cancer. Primary or secondary endocrine resistance is a
major clinical challenge in the management of patients with
advanced hormone-receptor–positive breast cancer because it
is a dynamic phenomenon including development of estro-
gen-receptor (ESR1) mutations. The evaluation and longitu-
dinal monitoring of endocrine resistance including enumer-
ation of CTCs,measurement of heterogeneous estrogen-recep-
tor expression in those cancer cells and detection of ESR1
mutations allows real-time molecular monitoring allowing
to adapt treatment modalities with potential impact on
outcome.
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Single CTC isolation
Briefly, for each CellSearch enriched sample, 13 mL were
loaded with 325 mL manipulation buffer (SB115, Silicon
Biosystem) into an A300K cartridge. Approximately 8.6 mL of
the sample is de facto dielectrophoretically processed in which
cells are individually trapped in cage. The cartridge is then
scanned by an automated fluorescence microscope and cells
detected by DAPI staining. Three different populations of cells
were isolated: (i) ERþ CTCs, defined as ER-positive, CK-8,
CK-18, CK-19–positive, CD45-negative; (ii) ER# CTCs, defined
as ER-negative, CK-positive, CD45-negative; and (iii) WBCs,
defined as CD45-positive, ER#, and CK-negative. Each cell was
collected individually, washed two times in PBS and stored at
#80"C or immediately lysed in accordance with MALBAC
protocol (35). To minimize DNA contamination in the same
isolation cage containing the individual cell, an aliquot of the
elution buffer from the single cage was MALBAC-amplified and
subjected to DNA Sanger sequencing. No mutation was
detected on all elution buffer reactions. Moreover, for each
sequencing run, a no template control was tested.
Whole genome amplification
Cell lysis and genome amplification was performed using the
MALBACkit (YikonGenomics YK001A/B version 1302.1; ref. 33),
following themanufacturer's instructions. A negative no template
control (NTC), a blank control (SB115), and a MALBAC-positive
control were used for eachMALBAC reaction.WGAproducts were
then purified according to the Agencourt AMPure XP bead kit
(Beckman Coulter) manufacturer's protocol (36) and QC using
Qubit dsDNA High Sensitivity Assay kit (ThermoFisher). WGA
products were run on 0.8% (v/v) agarose gel and checked for
expected distribution in size (300–2,000 bp).
Sanger sequencing
Sanger sequencing was performed to genotype all WGA pro-
ducts as well as 14 hotspot mutations in the ESR1 gene found in
MBC tissues and related controls on an AB 3730 following the
manufacturer's protocol. Detailed PCR conditions (Tm) and
primer sequences are available in Supplementary Methods
(Table 1). Sequences were analyzed and genotyped by SeqScape
v3.0 analysis software (ThermoFisher).
Results
To investigate whether detection of ESR1 mutations in indi-
vidual CTCs in MBC patients could be used as a tool to enable
monitoring of themetastatic burden for clinical decision-making,
a 4-step protocol was implemented with the following workflow:
(i) CTC enrichment, (ii) single cell isolation, (iii) whole genome
amplification, and (iv) Sanger sequencing (Fig. 1).
Patient and pathological features
A cohort of 30MBC patients was characterized by amedian age
of 56 years. Patients (36.6%) showed evidence of one single
metastatic lesion, while 64% showed more than one at the time
of the first draw. Clinical and pathological features of primary and
metastatic tumor tissues are summarized in Table 1. Among the
total number of patients, 28 had histologically confirmed ER
positivity even at metastatic sites. At the time of surgery, primary
tumor tissues were investigated for presence of ER mutations and
all harbored a wild-type genotype.
Enrichment, isolation, and genome amplification of
individual CTCs
Enrichment and enumeration of CTCs performed on Cell-
Search involved a total of 50 blood samples taken from the 30
patients enrolled. The number of CTCs based on ER expression
(Fig. 2) for each patient (ID) are shown in Table 2. Overall, the
average of total CTCs enumerated was 80, with a maximum of
1,375 cells. Samples (22%) were negative (no CTCs) for the
presence of CTCs, defining a group of patients currently respon-
sive to current treatment. The remaining 39 samples were divided
into two groups depending on the established cutoff of 5 CTCs
(37) used to identify patients with high risk of disease progression
(12 samples <5 CTCs vs. 27 samples $5 CTCs). Only 4 of the 50
samples analyzed showed a number of CTCs greater than or equal
to 20 and were processed on the DEPArray. Seventy-one single
CTCs and 12 white blood cells (WBC) were retrieved. Forty of
these CTCs and all theWBCswere subjected toWGA. The number
of CTCs (subdivided in ERþ or ER#) isolated for each individual
patient and the corresponding number of selected cells for WGA
are summarized in Table 3. Samples processed on DEPArray
showed between 21% and 30% of CTCs recovered.
Preclinical validation of single-cell genome
amplification and analysis
Validation of single-cell genome amplification was con-
ducted on 30 individual single cells. DNA-positive controls,
after MALBAC amplification showed heterozygosity for the
BRAF V600E (c.1860T>a) mutation (data not shown), as
expected. No other BRAF mutations were found in all the
wild-type single cells analyzed, demonstrating feasibility of the
protocol.
Following spiking, enrichment and immune labeling, 91 pos-
itive CTCs were detected by CellSearch. Sixty-five percent of these
CTCs were identified on the DEPArray and finally 10 individual
cells were recovered and subjected to whole genome amplifica-
tion. In addition, 10WBCswere recovered and subjected toWGA,
as negative control. The sequences obtained from all the C4-2
Table 1. Clinicopathologic features of 30 MBCs
Clinicopathologic features Detail n
Age Median 56
Minimum 34
Maximum 79
Histology Ductal 18
Lobular 7
Other 2
Missing 3
Type IBC 16
No IBC 14
ER Positive 30
Negative 0
PR Positive 20
Negative 10
HER2 Positive 2
Negative 24
Missing 4
Metastasis sites n ¼ 1 11
n > 1 19
ER metastatisa Positive 28
Negative 2
PR metastasisa Positive 20
Negative 10
Abbreviation: IBC, inflammatory breast cancer.
aER and PR status immunohistochemistry on available metastatic lesions.
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cells (single or pooled) revealed all 7 carried known muta-
tions (AR/T878A, CDH1/P94T, CDK4/P110L, ErbB2/E930D,
ETV1/G207E, NCOR2/L167P, PIK3C3/F524C; data not shown).
Sequences obtained from the 10 WBCs from healthy donor's
buffy coat showed wild-type genotypes for all variants tested.
ESR1 mutational analysis in single CTCs
ESR1 mutation analysis was successfully performed on all
single cells isolated. All mutations were located within the
ligand-binding domain of the ESR1 gene in exons 4, 5, 6, 7, and
8 (Fig. 3). All 12 WBCs showed a wild-type genotype confirming
the absence ofmutations in the germline. Overall, we found ESR1
mutations in a total of 8 CTCs belonging to 2MBC patients. High
levels of intra- and intertumor genetic heterogeneity in ER-pos-
itive CTCs populations was also revealed. The remaining 32 CTCs
analyzed showed a wild-type ESR1 genotype. For patient ID20, a
total of 5 single CTCs were analyzed and all showed wild-type
phenotype. Patient ID19 exhibited a heterogeneous ESR1 geno-
type in their CTC populations. Among the ERþ CTC population,
we detected 3 different genotypes: (i) one single wild-type CTC;
(ii) 3 CTCs heterozygous for a single mutation (Y537S) in exon 8
(Fig. 3a); (iii) one single CTC homozygous for the same Y537S
(LOH; Fig. 3b).Matching cfDNAwas tested, confirming theY537S
mutation at 0.25%allele frequency. Patient ID10was theonly one
who had 2 serial blood samples taken, 3 months apart. The first
sample showed an ESR1 wild-type genotype in all the 12 CTCs
recovered. The second showed a wild-type genotype in all 8 ER#
CTCs, and in 4 of the ERþ CTCs recovered. Three CTCs were
heterozygous for the Y537Smutation, whereas the remaining ERþ
CTC harbored 2 different mutations in exon 8. Other than the
Y537S we found a new mutation, not reported until now, the
T570I (Fig. 3c). Also, in this case, data were compared with those
obtained on matching cfDNA. No mutation was detected at the
first draw, while Y537S was detected at the second sampling at a
percentage of 0.18%.
Correlation between ESR1 mutation and patients' treatment
Patient ID19 with the Y537S mutation had only one sampling
for CTC enumeration and circulating free tumor DNA (cfDNA)
analysis. The first diagnosis of inflammatory ductal breast cancer
was made in 2010, and the patient opted for holistic remedies.
In 2011, the patient developed ascites and pleural effusions
and started a chemotherapeutic treatment (docetaxel–cytoxan)
for 6 months, followed by endocrine therapy with aromasin.
In 2014, the patient was subjected to 6 cycles of Doxil and
Faslodex, but in January 2015, a liver metastasis was found. This
progression to metastatic disease during treatment indicated a
failure in the therapeutic approach. The analysis of CTCs and
cfDNA confirmed this suspicion, with the finding of the Y537S-
activating mutation.
Patient ID10 reported twomutations, the Y537S and the newly
reported T570I. This case report shows how the monitoring of
ESR1 mutations can be crucial to monitor and predict disease
evolution. First diagnosis was made in 2011, which was followed
by a mastectomy. In 2012, she was irradiated and subsequently
treatedwith tamoxifen. Due to poor tolerability of the drug and to
the occurrence of bonemetastasis, the patient switched endocrine
therapy, examestane followed by fulvestrant. At the time of the
Figure 1.
Study workflow. The total number of
CTCs analyzed from 3 different
patients who showed a number of
ERþ CTCs > 20. For each patient, 3
WBC were recovered as negative
controls. Onepatientwas tested twice
because of disease progression.
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first draw, she was negative for ESR1 mutations, but a high
increase in the number of CTCs was found compared with
baseline CTCs count (80 vs. 54). The second sampling was taken
only 1 month apart and was positive for the Y537S-activating
mutation. Furthermore, a third CTC count was made after a
further therapy switch to combination with palbociclib, showing
a relative decrease in total number of CTCs (43 vs. 80), but an
almost unchanged number of the ERþ population (23 vs. 28). The
prospective clinical evidence clearly indicate that the patient did
not benefit from fulvestrant at time of ESR1 mutation detection.
Instead, she benefited from the prompt switch to a combined
therapy of palbociclib and fulvestrant, a highly effective regimen
evaluated in the prospective, randomized, phase III study
PALOMA-3, whose benefit appears irrespective of common geno-
mic abnormalities such as ESR1 and PI3KCA (38, 39).
Discussion
The frequency of ESR1mutations in breast cancer is a matter of
intense debate for the potential clinical utility of this information.
Primary ESR1mutations are relatively rare in primary tissue, up to
7% of specimens analyzed with very low allele frequencies
(0.07%–0.2%), when compared with a much higher detection
in patients with metastatic disease (11). The first study on the
detection of ESR1 mutations in patients that were exposed to
endocrine therapy was conducted on metastatic biopsies and
matched cfDNA samples (37). Two hotspot mutations in codons
537 and 538 of the ESR1 gene were investigated by digital PCR
(dPCR). Those findings showed monitoring ESR1 mutations by
dPCR was feasible, but not all mutations found in the metastatic
biopsies were detected also inmatched cfDNA (40). In our study,
we used the analysis on cfDNA as a validation of the results found
at the CTC level. Allmutations found in cfDNAwere confirmed in
the ERþCTC population. In CTCs, we detected a newmutation in
codon 8 (T570I) that was not detected in cfDNA. On the other
hand, ER expression inCTCs showed awide heterogeneous status.
Most samples positive for CTCs showed amixed population (ERþ
and ER#), but 5 samples positive for CTCs were negative for ER
expression. These results suggest that analysis of both CTCs and
cfDNA can be a useful guide in clinical practice.
Figure 2.
ER nuclear expression. Representative
CellSearch images for (A) ER
expression in the MCF-7 cell line
(events 1, 2, 3 are ER#, events 4 and 5
are ERþ); (B) CTCs from patient
sample (all events are ERþ).
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Our study is the first in which the combined systems (Cell-
Search and DEPArray) were applied to assess both ER expres-
sion and all 14 ESR1 hotspot mutations by the MALBAC single-
cell amplification method. The combined approach, CellSearch
and DEPArray, was tested already on cancer patients' samples
(41–43). In a previous study, 510 CTCs were isolated from 66
MBCs. Thirty-seven CTCs were subjected to adaptor–ligation-
mediated whole-genome amplification and subsequently ana-
lyzed for the expression of the ErbB2 gene and for analysis of
two hotspots in PIK3CA (exons 20 and 9; ref. 41). They
demonstrated applicability of that workflow and also found
some heterogeneity between the analyzed CTCs and primary
tumor. Another group studied the entire population of CTCs
and white blood cells enriched from the CellSearch system to
genotype ESR1, PIK3CA, TP53, FGFR1, and FGFR2 genes, by a
next-generation sequencing (NGS) panel. Analysis of such
markers was also done on cfDNA and 4 repeated samples over
time during patient therapy monitoring. Two patients showed
changes at the level of ESR1 gene mutations detected in cfDNA,
only one in cfDNA and CTCs. This discordance can be
explained by the fact that CTCs were analyzed as a pool with
WBCs, where the predominant component is wild-type (42).
Only recently the same group published a new study where the
NGS panel was also performed on single CTC isolated by
DEPArray. The purpose of the study was to determine whether
cfDNA can be compared with single CTC analysis to detect
tumor mutation heterogeneity (44).
Our work is the first to evaluate detection of all activating ESR1
mutations among the LBD, at the single circulating tumor cell
level in MBC patients. We also monitored the acquisition of
endocrine resistance and validated data confirming mutations in
matched cfDNA. Of the 4 samples processed and corresponding
to 3 different patients, 2 had at least one mutation that was also
confirmed in cfDNA, but not in primary tissue. In both samples,
themutation detectedwas Y537S, positioned in exon8of the LBD
domain of ER, as well as one of the most common mutations
found in metastatic lesions. This mutation was present only in
some of the CTCs from the same patient, highlighting the impor-
tance of single cell analysis instead of the previously pooling
strategy (40, 42).
The role ofwild-type tyrosine 537 and the effects of a number of
possible amino acid substitutions have been thoroughly investi-
gated (13). This site is located in domain E, ligand binding, and
recognition region, containing the functional transcription acti-
vating domain ligand dipendene-2 and involved in the regulation
of ER transcriptional activity. Among all the substitutions tested,
the Y537S was the only one that showed 100% activity of the
receptor in the absence of ligand (45). A recent study showed that
such activity can be partially reduced by increasing the tamoxifen
or fulvestrant doses, a possible strategy to avoid endocrine resis-
tance (46). This mutation could definitely be one of the main
causes of poor or inadequate response to hormone therapy.
Finally, we also demonstrate how our workflow allows inves-
tigation of intratumor heterogeneity. A loss of heterozygosity
(LOH) was detected in one single CTC. We cannot totally exclude
that this may be due to a technical error deriving from WGA.
Analyzing a higher number of CTCs for each patient has in part
solved this issue. For the first time, in our work,MALBAChas been
used in combination with the CellSearch and the DEPArray
systems. None among the various techniques can ensure the
Table 2. CTC number assessed by CellSearch for each patient, based on ER surface expression
Patient ID CTCþ/ER# CTCþ/ERþ Total Patient ID CTCþ/ER# CTCþ/ERþ Total
1 0 0 0 15a 9 18 27
2a 1 3 4 0 1 1
3 1 4 16a 147 0 147
3 0 0 0 410 0 410
4 0 0 0 17 0 2 2
4 1 0 1 18a 13 15 28
5a 2 2 4 5 14 19
0 2 2 19 19 33 52
6 0 6 20a 12 44 56
6 3 0 3 13 9 22
7a 3 0 3 21 0 0 0
2 2 4 22a 1,361 14 1,375
8 0 5 5 931 0 931
9 2 2 4 23 0 0 0
10a 11 43 54 24 0 0 0
22 58 80 25 22 18 40
10 13 31 44 26 19 9 28
11 0 0 0 27 0 0 0
12 5 0 5 28 0 0 0
13 1 0 1 29 0 0 0
14 2 3 5 30 0 0 0
aMore than one draw was performed during the enrollment period.
Table 3. Summary of the number of CTCs detected, isolated, and selected to perform WGA
Patient ID
No. of CTCs on
CellSearch ER(þ, #)
No. of CTCs on
DEPArray ER(þ, #)
% of CTCs
recovered
No. of WGA
performed on ER(þ, #)
No. of WGA
performed on WBCs
19 56 (44, 12) 17 (8, 9) 30 7 (5, 2) 3
20 52 (33, 19) 11 (6, 5) 21 5 (3, 2) 3
10a 54 (43, 11) 15 (11, 4) 28 12 (8, 4) 3
10a 80 (28, 52) 19 (8, 11) 23 16 (8, 8) 3
aTwodrawswere performedduring the enrollment period; a third count onCellSearchwas performed and showed adecrease in the total number of CTCs (44), but an
almost stable number of ERþ CTCs (23).
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absence of errors like false positive/negative results or allelic
dropout (ADO). Several comparison studies have shown that
each WGA technique has its own benefits and drawbacks. The
main advantages of MALBAC are associated with reduced ADO
and PCR bias, high amplification efficiency even of GC-rich
regions andhigh genome coverage (up to90%; ref. 47).Moreover,
an improved ability of MALBAC in SNP variant identification has
been recently reported,withbetter performance inuniformity and
reproducibility (48). Other methods, like SurePlex, allow for a
better copy-number alterations (CNA) detection, with a more
uniformity of amplification across the genome (49). These obser-
vations led us to endorse MALBAC as the technique to be used in
genotyping the ESR1 gene. MALBAC is therefore confirmed by us
to be a reliable WGA method to address single CTC molecular
profiling.
In conclusion, this study demonstrated the feasibility of our
protocol to detect andmonitor ESR1 genemutations at the single
CTC level in MBCs. Early detection is essential to set the correct
treatment plan for patients, before onset of metastatic disease. In
addition, analysis of individualCTCs could allow identificationof
new potentially driving mutations or even new genes involved in
resistance. Further studies with larger numbers of patients are
required to make this approach of use in the clinic.
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